Dr. Anurag Singh, CSO of Timeline Nutrition and an MD/PhD with deep expertise in immunology and mitochondrial biology, delivers one of the most technically dense and clinically actionable discussions on Urolithin A available. The episode centers on mitophagy—the selective autophagy of damaged mitochondria—and why its decline is a core hallmark of aging. Singh explains the precise molecular mechanism: Urolithin A binds to and stabilizes the PINK1/Parkin pathway, tagging dysfunctional mitochondria for lysosomal degradation without triggering apoptosis or affecting healthy organelles.
Listeners get a direct walkthrough of two pivotal trials. The ATLAS trial (elderly, sedentary adults) showed 1000mg daily for 4 months yielded a 12% increase in maximal leg press strength and a 10% improvement in VO2 max, with effects plateauing after week 8—suggesting a loading phase followed by maintenance. The MitoImmune trial demonstrated a 20% increase in mitochondrial mass within CD8+ T-cells, linking mitophagy directly to immune function and reduced inflammaging. Singh also addresses the critical gut-microbiome bottleneck: only ~30% of people naturally convert dietary ellagitannins (pomegranate, walnuts) into Urolithin A, making direct supplementation the only reliable strategy for non-converters. Dosing guidance is precise: 500mg for younger populations seeking healthspan maintenance, 1000mg for clinically meaningful muscle and immune outcomes in older adults. The episode closes with a look at ongoing blood-brain barrier research and the potential for Urolithin A to clear senescent mitochondria in microglia, positioning it as a broad-spectrum geroprotective intervention rather than a narrow muscle supplement.
Key Insights
- Urolithin A induces mitophagy by triggering a specific conformational change in the PINK1/Parkin pathway, clearing dysfunctional mitochondria without harming healthy ones—unlike general antioxidants.
- The ATLAS trial demonstrated a 12% increase in muscle strength (leg press, hand grip) and a 10% improvement in VO2 max in older adults over 4 months at 1000mg daily, with effects plateauing after 8 weeks.
- The MitoImmune trial showed a 20% increase in mitochondrial mass within immune cells (CD8+ T-cells), directly linking mitophagy to enhanced immune surveillance and reduced inflammaging markers.
- Only ~30% of people harbor the gut microbiome strains (Gordonibacter) capable of converting ellagitannins into Urolithin A, making direct supplementation the only reliable route for non-producers.
- Dosing is bifurcated: 500mg daily for general healthspan maintenance in younger populations; 1000mg daily for clinically significant muscle and immune outcomes in 50+ adults, with no added benefit above 1000mg.
- Ongoing research is testing Urolithin A's ability to cross the blood-brain barrier, with preliminary data suggesting it may reduce neuroinflammation by clearing senescent mitochondria in microglia.
Who should listen: Clinicians and self-experimenters who want the raw trial data, mechanistic pathways, and dosing thresholds for a mitophagy intervention—not a marketing pitch.
Why This Matters
Urolithin A represents a shift from blanket antioxidant approaches to targeted quality-control interventions—clearing senescent mitochondria rather than just dampening ROS. For practitioners tracking the convergence of geroscience and precision supplementation, the gut-microbiome gatekeeping problem (only 30% natural converters) makes this a litmus test for biomarker-driven protocols.
